Mark Heinen - 01 Mar 2023 Form 4 Insider Report for Better Therapeutics, Inc.

Role: Chief Financial Officer
Signature: /s/ Mark Heinen
Issuer symbol: BTTX on OTC
Transactions as of: 01 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 21 Apr 2023, 18:14:15 UTC
Previous filing: 02 Dec 2022
Next filing: 19 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BTTX	Common Stock	Award	$0	+54,000	+63%	$0.000000	139,723	05 Apr 2023	Direct	F1
holding	BTTX	Common Stock						2,281	01 Mar 2023	By daughter

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BTTX	Stock Option (Right to Buy)	Award	$0	+28,550		$0.000000	28,550	01 Mar 2023	Common Stock	28,550	$1.14	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares represent restricted stock units (each, an "RSU") granted on April 5, 2023, which vest as to 1/2 of the shares on March 24, 2024 and the remaining shares vest on March 24, 2025, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2	The stock option vests as to 1/4 of the shares subject to the stock option on March 1, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on March 1, 2023.